Core Viewpoint - The company Inke Medical has seen a significant increase in its stock price, closing at 29.77 yuan with a rise of 5.12%, while its rolling PE ratio has reached a new low of 12.09 times over the past 190 days, indicating potential undervaluation compared to the industry average [1] Company Summary - Inke Medical specializes in the research, production, and sales of high-performance personal protective products, including disposable nitrile gloves, PVC gloves, PE gloves, isolation gowns, masks, electric wheelchairs, manual wheelchairs, mobility scooters, walkers, electric sofas, bedside tables, ice/hot packs, hand sanitizers, heating pads, cooling mats, ECG electrodes, and label electrodes [1] - For the first quarter of 2025, the company reported a revenue of 2.494 billion yuan, representing a year-on-year increase of 13.20%, and a net profit of 353 million yuan, reflecting a year-on-year growth of 48.08%, with a gross profit margin of 24.16% [1] Industry Summary - The average PE ratio for the medical device industry stands at 51.87 times, with a median of 37.48 times, positioning Inke Medical at the 32nd rank within the industry [1] - As of the first quarter of 2025, a total of 18 institutions hold shares in Inke Medical, including 16 funds, 1 social security fund, and 1 other entity, with a total holding of 52.99 million shares valued at 1.266 billion yuan [1]

7月7日，鱼跃医疗今日收盘34.71元，下跌2.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到19.65倍，总市值347.96亿元。 资金流向方面，7月7日，鱼跃医疗主力资金净流出3461.12万元，近5日总体呈流出状态，5日共流出 13176.85万元。 江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2025年一季报，公司实现营业收入24.36亿元，同比9.17%；净利润6.25亿元，同 比-5.26%，销售毛利率50.30%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13鱼跃医疗19.6519.272.65 ...

Company Overview - Dirui Medical's closing price on July 4 was 14.03 yuan, down 1.06%, with a rolling PE ratio of 106.87 times and a total market capitalization of 3.826 billion yuan [1] - The company ranks 106th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1][2] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, and blood cell analysis [1] Financial Performance - In the first quarter of 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1] - The company holds 213 patents, including 136 invention patents and 96 software copyrights [1] Market Activity - On July 4, Dirui Medical experienced a net outflow of 1.1247 million yuan in principal funds, although the overall trend over the past five days showed a net inflow of 9.9255 million yuan [1]

Company Overview - Shenzhen Huatai Medical Devices Co., Ltd. specializes in the research, production, and sales of electrophysiological and interventional medical devices [1] - The main products include electrophysiological devices, coronary access devices, peripheral vascular interventional devices, and non-vascular interventional medical devices [1] Financial Performance - For Q1 2025, the company reported revenue of 564 million yuan, representing a year-on-year increase of 23.93% [1] - The net profit for the same period was 183 million yuan, showing a year-on-year growth of 30.69% [1] - The gross profit margin stood at 73.09% [1] Market Position - As of July 1, the company's stock closed at 304.5 yuan, with a price increase of 2.53% [1] - The rolling price-to-earnings (PE) ratio reached 59.96 times, while the average PE ratio for the medical device industry is 51.70 times [1][2] - The total market capitalization of the company is 42.939 billion yuan [1] Institutional Holdings - As of Q1 2025, a total of 109 institutions hold shares in Huatai Medical, including 106 funds and 3 other entities, with a total holding of 47.1568 million shares valued at 18.264 billion yuan [1]

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Jianfan Biological Technology Group Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [2] - As of June 5, the closing price of Jianfan Biotech was 21.77 yuan, with a rolling PE ratio of 24.01 times, and a total market capitalization of 17.386 billion yuan [1] - The company ranks 51st in the medical device industry, which has an average PE ratio of 50.97 times and a median of 36.67 times [1][3] Group 2 - Jianfan Biotech specializes in the research, production, and sales of biomaterials and high-tech medical devices, with key products including various blood purification devices and consumables [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] - As of March 31, 2025, the number of shareholders increased to 52,502, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Haohai Biological Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of June 3, the company's stock closed at 53.32 yuan, with a rolling PE ratio of 30.09, marking a new low in 28 days, and a total market value of 12.434 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Haohai Biological at the 66th rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 619 million yuan, reflecting a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% year-on-year, with a gross margin of 69.52% [1] - As of the Q1 2025 report, three institutions hold shares in Haohai Biological, with a total of 2.4635 million shares valued at 146 million yuan [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)88春立医疗51.5752.752.2965.94亿行业平均 50.8049.074.67108.36亿行业中值36.7136.842.4850.19亿1天益医疗-1758.71-3012.481.8822.41亿2澳华内 镜-655.90328.975.2569.12亿3诺唯赞-427.65-505.802.3591.52亿4爱朋医疗-397.87302.264.7932.65亿5博晖 创新-335.73532.763.5849.26亿6奥精医疗-136.87-200.611.8125.40亿7硕世生物-136.24-1990.831.2239.85亿 8睿昂基因-101.37-83.231.4413.12亿9康泰医学-88.33-74.633.1558.14亿10中红医疗-72.73-58.010.9250.55亿 11热景生物-55.61-64.074.10122.37亿 本文源自：金融界 截至2025年一季报，共有13家机构持仓春立医疗，其中基金8家、其他4家、券商1家，合计持股数 3163.07万股，持股市值4.29亿元。 北京市春立正达医疗器械 ...

Company Overview - The company, Shanghai TuoJing Life Technology Co., Ltd., specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1] - The main products include in vitro diagnostic reagents, instruments, and service revenue [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - For Q1 2025, the company reported operating revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - The net profit for the same period was 471,700 yuan, showing a year-on-year increase of 110.51% [1] - The gross profit margin was reported at 63.66% [1] Market Position - As of May 22, the company's stock closed at 13.8 yuan, down 1.64%, with a rolling price-to-earnings (PE) ratio of 56.96 times [1] - The total market capitalization is 2.25 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 48.71 times, with a median of 35.37 times, placing the company at the 93rd position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 17,040, a decrease of 590 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Core Insights - Yuyue Medical's stock closed at 35.8 yuan, with a PE ratio of 20.26, marking a new low in 26 days, and a total market capitalization of 35.889 billion yuan [1] - The average PE ratio in the medical device industry is 49.84, with a median of 36.65, placing Yuyue Medical at the 47th position [1][2] - As of April 18, 2025, Yuyue Medical has 40,000 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Yuyue Medical specializes in the research, manufacturing, and sales of medical devices, focusing on areas such as respiratory oxygen, diabetes care, infection control solutions, home electronic testing, in vitro diagnostics, emergency and clinical rehabilitation equipment [1] - The company owns several major brands, including "Yuyue," "Jiefuro," "Hua Tuo," "Jin Zhong," "An Er Iodine," "Primedic," and "Liuliu Vision," with significant brand value and advantages due to product performance and effective brand communication [1] Financial Performance - In Q1 2025, Yuyue Medical reported revenue of 2.436 billion yuan, a year-on-year increase of 9.17%, while net profit was 625 million yuan, reflecting a year-on-year decrease of 5.26%, with a gross profit margin of 50.30% [2] - The company's PE (TTM) is 20.26, with a static PE of 19.88 and a price-to-book ratio of 2.74 [2]

5月6日，安杰思今日收盘59.55元，上涨1.78%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到16.24倍，总市值48.22亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。报告期内，公司取得重要政府荣誉7项，获 得"浙江省级企业技术中心"、"浙江省生物医药高成长型企业"、"浙江省首批两新重大科技成果"、"杭 州市绿色工厂"、"杭州市优质产品（止血夹）2023年杭州市总部企业"等荣誉。 最新一期业绩显示，2025年一季报，公司实现营业收入1.29亿元，同比15.27%；净利润5624.83万元， 同比6.57%，销售毛利率70.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)40安杰思16.2416.441.9648.22亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99- ...